文献リスト

1）Yamada R, Sato M, Kawabata M, et al. Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology. 1983; 148: 397-401

2）Nakamura H, Oi H, Sawada S. Trancatheter oily chemoembolization of hepatocellular carcinoma. Radiology. 1989; 170: 783-6

3）Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010; 33: 41-52

4）Raoul JL, Sangro B, Forner A, et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev. 2011; 37: 212-20

5）Lencioni R, Petruzzi P, Crocetti L. Chemoembolization of hepatocellular carcinoma. Semin Intervent Radiol. 2013; 30: 3-11

6）Golfieri R, Giampalma E, Renzulli M; PRECISION ITALIA STUDY GROUP. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcino-ma. Br J Cancer. 2014; 111: 255-64

7）Sacco R, Bargellini I, Bertini M, et al. Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol. 2011; 22: 1545-52

8）Irie T, Kuramochi M, Takahashi N. Dense accumulation of lipiodol emulsion in hepatocellular carcinoma nodule during selective balloon-occluded transarterial chemoembolization: measurement of balloon-occluded arterial stump pressure. Cardiovasc Intervent Radiol. 2013; 36: 706-13

9）Ebara M, Ohto M, Sugiura N, et al. Percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Study of 95 patients. J Gastroentel Hepatol. 1990; 5: 616-26

10）Seki T, Wakabayashi M, Nakagawa T. Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma. Cancer. 1994; 74: 817-25

11）Tacke J, Mahnken A, Roggan A, et al. Multipolar radiofrequency ablation: first clinical results. RoFo. 2004; 176: 324-9

12）Ritz JP, Lehmann KS, Reissfelder C, et al. Bipolar radiofrequency ablation of liver metastases during laparotomy. First clinical experiences with a new multipolar ablation concept. Int J Colorectal Dis. 2005; 21: 25-32

13） Frericks BB, Ritz JP, Roggan A, et al. Multipolar radiofrequency ablation of hepatic tumors: initial experience. Radiology. 2005; 237: 1056-62

14）椎名秀一朗，寺谷卓馬，小尾俊太郎，他．Cool-tip型電極を用いた経皮的ラジオ波焼灼療法による肝細胞癌の治療．肝臓．2000; 41: 24

15）大崎往夫，木村　達，国立裕之，他．肝細胞癌に対する経皮ラジオ波熱凝固療法（RFA）の検討．肝臓．2001; 42: 22

16）Osaki Y, Nishikawa H. Treatment for hepatocellular carcinoma in Japan over the last three decades: Our experience and published work review. Hepatol Res. 2015; 45: 59-74

17）Lei JY, Wang WT, Yan LN, et al. Radiofrequency ablation versus surgical resection for small unifocal hepatocellular carcinomas. Medicine (Baltimore). 2014; 93: e271

18）Xu Q, Kobayashi S, Ye X, et al. Comparison of hepatic resection and radiofrequency ablation for small hepatocellular carcinoma: a meta-analysis of 16,103 patients. Sci Rep. 2014; 4: 7252

19）Gory I1, Fink M, Bell S, et al. Radiofrequency ablation versus resection for the treatment of early stage hepatocellular carcinoma: a multicenter Australian study. Scand J Gastroenterol. 2015; 50: 567-76

20）Yi HM, Zhang W, Ai X, et al. Radiofrequency ablation versus surgical resection for the treatment of hepatocellular carcinoma conforming to the Milan criteria: systemic review and meta-analysis. Int J Clin Exp Med. 2014; 7: 3150-63

21）Liu PH, Hsu CY, Hsia CY, et al. Surgical Resection Versus Radiofrequency Ablation for Single Hepatocellular Carcinoma ≤2 cm in a Propensity Score Model. Ann Surg. 2015 Mar 13. [Epub ahead of print]

22）Hasegawa K, Kokudo N, Shiina S, et al. Surgery versus radiofrequency ablation for small hepatocellular carcinoma: Start of a randomized controlled trial (SURF trial). Hepatol Res. 2010; 40: 851-2

23）Osaki Y, Ikeda K, Izumi N, et al. Clinical effectiveness of bipolar radiofrequency ablation for small liver cancers. J Gastroenterol. 2013; 48: 874-83

24）Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359: 378-90

25）Llovet JM, Peña CE, Lathia CD, et al. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2012; 18: 2290-300

26）Takeda H, Nishikawa H, Osaki Y, et al. Clinical features associated with radiological response to sorafenib in unresectable hepatocellular carcinoma: a large multicenter study in Japan. Liver Int. 2015; 35: 1581-9

27）Arao T, Ueshima K, Matsumoto K, et al. FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma. Hepatology. 2013; 57: 1407-15

28）Sakai K, Takeda H, Nishijima N, et al. Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib.Oncotarget. 2015 May 25. [Epub ahead of print]

29）Okita K, Izumi N, Matsui O, et al. Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study. J Gastroenterol. 2015; 50: 191-202

30）Bruix J, Takayam T, Mazzaferro V, et al. STORM: A Phase Ⅲ, Randomized, Double-bind, Placebo-controlled Trial of Adjuvant Sorafenib after Resection or Ablation to Prevent Recurrence of Heoatocellular Carcinoma. ASCO 2014, abstract 4006

31）Kudo M, Imanaka K, Chida N. Phase III study of sorafenib after transarterialchemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer. 2011; 47: 2117-27

32）Kudo M, Han G, Finn RS, et al. Brivanib as Adjuvant Therapy to Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma: A Randomized Phase III Trial. Hepatology. 2014; 60: 1697-707

33）Joong-Won Park, Ann-Lii Cheg, Masatoshi Kudo, et al. A randomized, double-blind, placebo-controlled phase III trial of TSU-68 (Orantinib) combined with transcatheter arterial chemoembolization inpatients with unresectable hepatocellular carcinoma. EASL 2015, abstract G06

34）Cheng AL, Kang YK, Lin DY, et al. Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial. J Clin Oncol. 2013; 31: 4067-75

35）Johnson PJ, Qin S, Park JW, et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol. 2013; 31: 3517-24

36）Cainap C, Qin S, Huang WT, et al. Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol. 2015; 33: 172-9

37）Llovet JM, Decaens T, Raoul JL. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol. 2013; 31: 3509-16

38）Zhu AX, Kudo M, Assenat E, et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. JAMA. 2014; 312: 57-67

39）Zhu AX, Park JO, Ryoo BY, et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2015; 16: 859-70

40）Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015; 372: 621-30

41）Anthony B, El-Khoueiry, Ignacio M, et al. Phase 1/2 Safety and Antitumor Activity of Nivolumab in Patients With Advanced Hepatocellular Carcinoma (HCC): CA209-040. ASCO 2015，abstract LBA101

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp